Astrazeneca (AZN) Revenue (2009 - 2026)

Astrazeneca (AZN) has reported Revenue for 18 consecutive years, with $77.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Revenue rose 4.05% year-over-year to $77.0 million; the TTM figure through Mar 2026 stood at $102.0 million (down 89.29% YoY), while the FY2025 annual figure was $58.7 billion, up 6263.92% from the prior year.
• Revenue came in at $77.0 million for Q1 2026 at Astrazeneca, up from $6.0 million in the prior quarter.
• The five-year high for Revenue was $815.0 million in Q4 2024, with the low at $3.0 million in Q2 2022.
• Average Revenue over 5 years is $134.7 million, with a median of $74.0 million recorded in 2025.
• Across the five-year window, Revenue jumped 6333.33% in 2023 and slumped 99.26% in 2025, its largest moves.
• Year by year, Revenue stood at $158.0 million in 2022, then surged by 75.32% to $277.0 million in 2023, then soared by 194.22% to $815.0 million in 2024, then plunged by 99.26% to $6.0 million in 2025, then soared by 1183.33% to $77.0 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $77.0 million, $6.0 million, and $11.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.